Skip to content

Phyllantus niruri mother tincture in non alcoholic fatty liver disease

An exploratory single arm clinical trial assessing the effectiveness of Phyllantus niruri mother tincture in non alcoholic fatty liver diseasein Muzaffarpur

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044256
Enrollment
35
Registered
2022-07-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K77- Liver disorders in diseases classified elsewhere

Interventions

Intervention1: Phyllanthus niruri: 10 drops in ½ cup of water twice daily after meals Control Intervention1: not applicable: not applicable

Sponsors

Dr Amit
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age: 18-60 years ii. Self reported cases of non-alcoholic fatty liver disease. iii. Patients with type 2 diabetes mellitus and dyslipidemia. iv. Patients with BMI more than 25kg/m2. v. Patients having Alanine aminotransferase (ALT) >40 U/L and Aspartate aminotransferase (AST)/ALT ratio >0.8 to < 1. vi. Ultrasound abdomen showing fatty liver. vii. Non alcoholics or consumption of less than 20 gm and 30 gm of alcohol per day in women and men respectively. viii. Both sexes. ix. Patients volunteering

Exclusion criteria

Exclusion criteria: Patients unwilling to take part or not giving consent to join the study. ii. Diagnosed cases of systemic diseases, psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any organ failure. iii. Known cases of endocrine disorders including Cushingâ??s syndrome or history of long term steroid intake or any other secondary causes of fatty liver. iv. Pregnancy and lactation. v. Substance abuse and/ or dependence. vi. Self reported immune-compromised state. vii. Undergoing homoeopathic treatment for any chronic disease within the last 6 months

Design outcomes

Primary

MeasureTime frame
Resolution of fatty liver on USG abdomen. ii. Improvement in liver enzymes (AST, ALT).Timepoint: All the outcome measures will be assessed at Baseline (0 month) and after 3 months.

Secondary

MeasureTime frame
36-Item Short-Form Health Survey (SF-36). ii. Change in body mass index. Timepoint: All the outcome measures will be assessed at Baseline (0 month) and after 3 months.

Countries

India

Contacts

Public ContactDr Amit

R.B.T.S Govt. Homeopathic Medical College and Hospital

amitrisdth@gmail.com7765802619

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026